The role of murine models in the development of antifungal therapy for systemic mycoses

Drug Resistance Updates

Volumn 3, Issue 6, 2000, Pages 364-383

  Graybill, John R ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN B DERIVATIVE; FLUCYTOSINE; GENACONAZOLE; ITRACONAZOLE; MICAFUNGIN; NYSTATIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; SAPERCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ASPERGILLOSIS; CANDIDIASIS; CHROMOMYCOSIS; CRYPTOCOCCOSIS; DRUG EFFICACY; DRUG TOLERABILITY; MINIMUM INHIBITORY CONCENTRATION; MUCORMYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC MYCOSIS;

EID: 0034496623     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2000.0171     Document Type: Article

References (235)

1. Treatment of murine cryptococcosis with liposome-associated amphotericin B
2. Amphotericin B in liposomes: A novel therapy for histoplasmosis
3. Efficacy of liposome-intercalculated amphotericin B in the treatment of systemic candidiasis in mice
4. Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits
5. Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans
6. Liposomal hamycin: Reduced toxicity and improved antifungal efficacy in vitro and in vivo
7. In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus
8. Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model
9. Comparison of amphotericin B and amphotericin B methyl ester: Efficacy in murine coccidioidomycosis and toxicity
10. Leukoencephalopathy in patients with amphotericin B methyl ester
11. Amphotericin B methyl ester and leukoencephalopathy: The other side of the coin
12. Clinical use of amphotericin B and derivatives: Lore, mystique, and fact
13. Comparative neurotoxicities of amphotericin B and its mono-methyl ester derivative in rats
14. Comparative pharmacokinetics of SCH 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys
15. Comparison of amphotericin B and-N-D-Ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis
16. Ornithyl amphotericin methyl ester treatment of experimental candidiasis in rats
17. Activity of MS-8209, a nonester amphotericin B derivitive, in treatment of experimental systemic mycoses
18. J. Treatment of murine disseminated candidiasis with L-743, 872
19. Comparative activity in vivo and toxicity of a new polyene, BRL 4954A and amphotericin B (amB)
20. Oral azole drugs as systemic antifungal therapy
21. Compounds active against cell walls of medically important fungi
22. Animal models for treatment of cryptococcosis
23. Efficacy of KY-62 (KY) in murine cryptococcosis and candidiasis
24. Pulmonary aspergillosis in mice: Treatment with a new triazole SCH39304
25. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872
26. Treatment of murine pulmonary aspergillosis with SCH56592 (SCH)
27. Itraconazole treatment of murine aspergillosis
28. Treatment of murine invasive candidiasis with amphotericin B and cilofungin: Evidence of enhanced activity with combination therapy
29. Treatment of murine pulmonary blastomycosis with SCH 51048, a broad-spectrum triazole antifungal agent
30. Activities of the triazole SCH 51048 against Coccidioides immitis in vitro and in vivo
31. Treatment of murine cryptococcal meningitis with UR-9751 and UR-9746
32. Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococal meningitis
33. Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice
34. Fluconazole treatment of Candida albicans infection in mice: Does in vitro susceptibility predict in vivo response?
35. Importance of Candida species other than C. albicans as pathogens in oncology patients
36. Resistance of Candida species to fluconazole
37. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States
38. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B
39. Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B and a muramyl dipeptide analog, alone and in combination
40. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome)
41. Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis
42. Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice
43. Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice
44. Amphotericin B liposomes with prolonged circulation in blood: In vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice
45. Superior efficacy of liposomal amphottericin B with prolonged circulation in blood in the treatment of severe candidiasis in leukopenic mice
46. Effect of attachment of anticandidal antibody to the surface of liposomes encapsulating amphotericin B in the treatment of murine candidiasis
47. Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits
48. Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model
49. Fluconazole versus Candida albicans: A complex relationship
50. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
51. Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model
52. Activity of a new triazole, SCH56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevesiae
53. In vitro activity of Schering 56592, compared with fluconazole and itraconazole against Candida spp.
54. Treatment of murine disseminated candidiasis with L-743,872
55. Treatment of disseminated Torulopsis glabrata infection with DO870 and amphotericin B
56. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
57. Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice
58. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated with prophylactically with fluconazole
59. Antifungal activity of voriconazole (UK-109,496), fluconazole, and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model
60. In vitro activity of a new pneumocandin antifungal agent, L-733,560, against azole-susceptible and -resistant Candida and Torulopsis species
61. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi
62. In vitro susceptibility of Candida blood stream isolates to a new echinocandin derivative, LY303366 and comparative antifungal agents
63. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates
64. Efficacy of FK4634, a 1,3-beta-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice
65. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis
66. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits
67. Itraconazole, a new triazole that is orally active in aspergillosis
68. Saperconazole therapy in a rabbit model of invasive aspergillosis
69. Efficacy of SCH56592 treatment and prevention of invasive pulmonary aspergillosis in persistently neutropenic rabbits
70. Itraconazole for experimental pulmonary aspergillosis: Comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma
71. Inhibition of monocyte-mediated damage to fungal hyphae by steroid hormones
72. Damage to hyphal forms of fungi by human leukocytes in vitro
73. Pathogenesis of pulmonary aspergillosis - Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression
74. Invasive aspergillosis
75. SCH56592 treatment of murine invasive aspergillosis
76. Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH28191
77. In vitro-in vivo correlations for the azole antifungals SCH56592 (56592), SCH39304 (39304), fluconazole (FCZ) and itraconazole (ITZ) in candidiasis and aspergillosis
78. Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids
79. Itraconazole resistance in Aspergillus fumigatus
80. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: Role of immune suppression
81. In vitro antifungal activity of L-743872 against a variety of moulds
82. In vitro studies with L-743,872, a water soluble pneumocandin: A comparative study
83. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
84. Evaluation of the echinocandin antifungal MK-0991 (L-743,872) efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
85. Low doses of pneumocandin L-743872, are effective in prevention and treatment in an animal model of pulmonary aspergillosis
86. In vitro activity of L-743872 against putatively amphotericin B (AmB) and fluconazole (Flu)-resistant Candida isolates
87. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis
88. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits
89. Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis
90. Efficacy of LY303366 against amphotericin B susceptible and resistant Aspergillus fumigatus in a murine model of invasive aspergillosis
91. Network EBGA. In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis
92. Correlation between in-vitro susceptibility testing to itraconazole abd in-vivo outcome of Aspergillus fumigatus infection
93. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs
94. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis
95. Model of recurrent pulmonary aspergillosis in rats
96. Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis
97. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: The potential role of bronchoalveolar D-manitol and serum galactomannan as markers of infection
98. Amphotericin B lipid complex therapy of experimental fungal infections in mice
99. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis
100. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice
101. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B
102. Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats
103. Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice
104. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis
105. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy
106. Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans
107. Sordarins: In vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi
108. Activities of sordarins in murine histoplasmosis
109. Efficacies of sordarin derivatives GM193663, GM211676, and GM237354 in a murine model of systemic coccidioidomycosis
110. Sordarins as antifungal compounds
111. Pulmonary cryptococcosis in the rat
112. Treatment of cryptococcal meningitis in mice with fluconazole
113. Fluconazole efficacy in animal models of mycotic diseases
114. Host defense in cryptococcosis. Protection of nude mice by thymus transplantation
115. Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis
116. Effect of fluconazole on antifungal activity of flucytosine in murine cryptococcal meningitis
117. An alternative animal model for comparison of treatments for cryptococcal meningitis
118. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis
119. Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for treatment of systmic murine cryptococcosis
120. Interaction of chemotherapy and immune defense in experimental murine cryptococcosis
121. Cryptococcosis in the acquired immunodeficiency syndrome
122. Improvements of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes
123. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis
124. Aerolized liposomal amphotericin B for treatment of pulmonary and systemic cryptococcus neoformans infections in mice
125. Chronic cryptococcal meningitis
126. Experiméntal cryptococcosis: Dissemination of Cryptococcus neoformans and dermotropism in guinea-pigs
127. Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304
128. Comparison of SCH39304 and its isomers, RR 42427 and SS 42426, for treatment of murine cryptococcal and coccidioidal meningitis
129. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
130. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species
131. 1, fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans
132. Liposomal amphotericin B therapy of murine histoplasmosis
133. Treatment of histoplasmosis with MK-991 (L-743,872)
134. Efficacy of the triazole D0870 in a murine model of systemic histoplasmosis
135. Treatment of murine histoplasmosis with UK 49,858 (fluconazole)
136. Experimental chemotherapy of histoplasmosis in nude mice
137. Experimental pulmonary histoplasmosis and emphysema
138. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in the murine model
139. Efficacy of nikkomycin Z in the treatment of murine histoplasmosis
140. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: Animal models
141. Comparison of fluconazole and amphotericin B in treating histoplasmosis in immunosuppressed mice
142. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis
143. Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model
144. Activities of the triazole D0870 in vitro and against murine blastomycosis
145. Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxcholate suspension against murine blastomycosis
146. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis
147. Evaluation of colifungin, a lipopeptide antifungal agent, in vitro against fungi isolated from clinical specimens
148. Efficacy of nikkomycin Z against experimental pulmonary blastomycosis
149. Experimental pulmonary fibrosis induced by Paracoccidioides brasilienseis conidia: Measurement of local host responses
150. Pulmonary paracoccidioidomycosis in resistant and susceptible mice: Relationship among progression of infection, bronchoalveolar cell activation, cellular immune response, and specific isotype patterns
151. Experimental murine paracoccidioidomycosis: Relationship among the dissemination of the infection, humoral and cellular immune responses
152. Host defense against experimental paracoccidioidomysosis
153. Cell-mediated immunity in host resistance against infection caused by Penicillium marneffei
154. Histopathological and electron microscopical studies on experimental Penicillium marneffei infection in mice
155. Current concepts: Coccidioidomycosis
156. Editorial response: Adequacy of therapy for coccicioidomycosis
157. Treatment of coccidioidomycosis with SCH39304
158. Efficacy of AmBisome on murine coccidioidomycosis
159. Activity of cilofungin against Coccidioides immitis: Differential in vitro effects in mycelia and spherules correlated with in vivo studies
160. Activity of the triazole SCH56592 against disseminated murine coccidioidomycosis
161. Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis
162. Treatment of murine coccidioidal meningitis with SCH39304
163. Phaeohyphomycosis caused by the fungal genera Bipolaris and Exserohilum
164. Invasive mold sinusitis: 17 cases in immunocompromised patients and review of the literature
165. Itraconazole treatment of phaeohyphomycosis
166. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis
167. SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei")
168. Cerebral phaeohyphomycosis caused by Ramichloridium obovoideum (Ramichloridium mackenziei): Case report
169. Cerebral phaeohyphomycosis caused by Ramichloridium obovoideum (Ramichloridium mackenziei): Case report - Comments
170. Experimental murine chromoblastomycosis mimicking chronic progressive human disease
171. Treatment of chronic chromoblastomycosis with the triazole SCH39304
172. Experimental zygomycosis due to Rhizopus species infection by various routes in guinea-pigs, rats, and mice
173. Effects of deferoxamine, ferroxamine and iron on experimental mucormycosis (zygomycosis)
174. Iron metabolism and fungal infections in patients with haematological malignancies
175. The role of iron in protozoan and fungal infectious diseases
176. Experimental zygomycosis in rabbits: Clinicopathological studies
177. Lack of activity of amphotericin B in systemic murine fusarial infection
178. Treatment of murine fusariosis with SCH 56592
179. Candidiasis in interferon-gamma knockout mice
180. Intrapulmonary response to Histoplasma capsulatum in gamma interferon knockout mice
181. Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis
182. Fluconazole and amphotericin B antifungal therapies do not negate the protective effect of endogenous tumor necrosis factor in a murine model of fatal disseminated candidiasis
183. Amphotericin B induces tumor necrosis factor production by murine macrophages
184. Combination immunotherapy and antifungal chemotherapy
185. IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma
186. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans
187. Interleukin-12 regulation of host defenses against Coccidioides immitis
188. Interleukin-12 is essential for a protective Th I response in mice infected with Cryptococcus neoformans
189. Modulation of immune responses in murine pulmonary histoplasmosis
190. Cytokine treatment of a central nervous system infection: Efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis
191. In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis
192. Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat
193. Granulocyte colony stimulating factor therapy of experimental murine cryptococcosis
194. Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis
195. Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice
196. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans
197. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans
198. R 5121 I (itraconazole) therapy of murine cryptococcosis
199. Effect of grapefruit juice on serum voriconazole concentrations in the mouse
200. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis
201. Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys
202. Efficacy of cilofungin therapy administered by continuous intravenous infusion for experimental disseminated candidiasis in rabbits
203. Antifungal effects of the nonlinear pharmacokinetis of cilofungin, a 1,3-beta-D-glucan synthase inhibitor, during continuous and intermittent infusions in treatment of experimental disseminated candidiasis
204. Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits
205. Discrepancy between in vitro and in vivo antifungal activity of albendazole
206. Treatment of murine cryptococcis with cyclosporin-A in normal and athymic mice
207. Effects of cyclopsorine in experimental cryptococal meningitis
208. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans
209. In vitro activiteis of terbinafine in combination with fluconazole and itraonazole against isolates of Candida with reduced susceptibility to azoles
210. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis
211. Combination therapy of experimental candidiasis, cryptococcosis, and aspergillosis in mice
212. Treatment of murine pulmonary cryptococcosis with ketoconazole and amphotericin B
213. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice
214. Combination therapy for systemic mycosis
215. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B
216. Interactions of amphotericin B and SCH 39304 in the treatment of experimental murine candidiasis: Lack of antagonism of a polyene-azole combination
217. Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis
218. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome
219. Use of amphotericin B with azole antifungal drugs: What are we doing?
220. Combined activity of amphotericin B and 5-fluorcytosine against Cryptococcus neoformans in vitro and in vivo in mice
221. The combined effects of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis
222. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis
223. Early mycological treatment failure in AIDS-associated cryptococcal meningitis
224. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS
225. Treatment of experimental cryptococcal meningitis with fluconazole: Impact of dose and addition of flucytosine on mycologic and pathophysiologic outcome
226. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
227. Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis
228. Synergy between cilofungin and amphotericin B in a murine model of candidiasis
229. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole
230. Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo